GlassScriptPhysician profile
Mary Massieu
NPI 1144644287
$4,423.84
in general payments reported to CMS, 2019-2025
35 companies · $501 in 2025
The $501 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $805 · 2022: $1,571 · 2023: $848 · 2024: $699 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,048.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $798.64 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $680.89 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $458.81 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $382.25 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $272.67 | 2021-2024 | Evenity, Prolia, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $218.97 | 2021-2023 | Glassia |
| Lilly USA, LLC | $200.13 | 2021-2023 | Mounjaro |
| Indivior INC. | $166.70 | 2022-2025 | Sublocade |
| Bayer Healthcare Pharmaceuticals INC. | $150.71 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $138.71 | 2021-2022 | |
| Pfizer INC. | $130.87 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $122.61 | 2021-2023 | |
| Organon LLC | $86.72 | 2022 | |
| Exact Sciences Corporation | $61.58 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $56.24 | 2025 | Abilify Asimtufii, Abilify Maintena |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $53.37 | 2023-2024 | Brixadi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.39 | 2022-2023 | |
| Medtronic, INC. | $37.70 | 2021 | |
| Boston Scientific Corporation | $35.78 | 2024 | |
| Novartis Pharmaceuticals Corporation | $35.65 | 2021-2023 | |
| Lucid Diagnostics INC. | $29.71 | 2022 | |
| Emd Serono, INC. | $29.32 | 2023 | Bavencio |
| Esperion Therapeutics, INC. | $27.77 | 2021 | |
| Abbott Laboratories | $25.01 | 2022 | |
| Neurocrine Biosciences, INC. | $22.97 | 2023 | Ingrezza |
| Tonix Medicines, INC. | $21.59 | 2025 | Tonmya |
| Bardy Diagnostics, INC. | $19.78 | 2022 | |
| Renalytix Ai, INC. | $18.48 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Amarin Pharma, INC. | $16.50 | 2021 | |
| Mylan Specialty L.P. | $15.85 | 2024 | Yupelri |
| Bioventus LLC | $15.40 | 2023 | Gelsyn-3 |
| Kowa Pharmaceuticals America, INC. | $14.36 | 2022 | |
| Tactile Systems Technology INC | $14.31 | 2022 | |
| Collegium Pharmaceutical, INC. | $13.59 | 2024 | Belbuca |
| Biohaven Pharmaceutical Holding Company LTD. | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Massieu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.